| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
Isoquinolin-1-amine (1532-84-9) does not have a defined pharmacological target as it is primarily a synthetic building block and biochemical assay reagent rather than a therapeutic agent. The compound is functionally related to isoquinoline derivatives, many of which exhibit diverse biological activities including kinase inhibition, antimicrobial, and anticancer properties. However, the parent compound itself is not known to bind to any specific protein or receptor. Its primary role is as a chemical intermediate for the synthesis of bioactive molecules with defined targets.
|
|---|---|
| ln Vitro |
Not applicable for Isoquinolin-1-amine (1532-84-9) as it is a synthetic intermediate without documented direct biological activity. The compound is classified as a biochemical assay reagent and building block for pharmaceutical synthesis. No IC50, EC50, or other potency values have been reported for this substance in the context of target-based assays. For its downstream derivatives synthesized from this intermediate, biological activities may vary widely depending on the final molecular scaffold and functional groups introduced.
|
| ln Vivo |
Not applicable for Isoquinolin-1-amine (1532-84-9) as it is a synthetic intermediate without documented in vivo biological activity. The compound is intended for chemical synthesis rather than pharmacological evaluation in animal models. It does not possess intrinsic therapeutic properties as a standalone agent. Any in vivo activity would be associated with the final drug compounds that incorporate this isoquinoline fragment, not with the intermediate itself. The compound is not typically administered to animals for efficacy studies.
|
| Enzyme Assay |
Not applicable for Isoquinolin-1-amine (1532-84-9) as it is a synthetic intermediate without reported receptor binding assays. For general organic chemistry applications, no protein or receptor binding assays have been reported. Standard analytical characterization for this compound includes NMR spectroscopy, GC analysis, and mass spectrometry for structural confirmation and purity determination (typically >98% by GC). These methods are used for quality control but are not biological binding assays.
|
| Cell Assay |
Not applicable for Isoquinolin-1-amine (1532-84-9) as it is a synthetic intermediate without cell-based activity. This compound is not typically used in cell culture experiments as a pharmacologically active agent. Its primary applications are in organic synthesis as a starting material for drug manufacturing. However, as a biochemical reagent, it may be used in proteomics research for chemical labeling or as a precursor for synthesizing more complex molecules that are subsequently tested in cell-based assays.
|
| Animal Protocol |
Not applicable for Isoquinolin-1-amine (1532-84-9) as it is a synthetic intermediate without documented in vivo animal study protocols. The compound is used as a chemical precursor rather than as a test article for animal efficacy studies. Any animal studies involving this compound would be for toxicological safety assessment of the chemical itself, not for therapeutic efficacy evaluation. Standard OECD guidelines for chemical safety testing could apply, but no specific protocols are reported in the available literature for this compound.
|
| ADME/Pharmacokinetics |
Not applicable for Isoquinolin-1-amine (1532-84-9) as it is a synthetic intermediate without reported pharmacokinetic studies. The compound is not intended for systemic drug delivery. For chemical safety evaluation, the compound has predicted physicochemical properties including moderate water solubility, but no formal PK data in humans or animals have been reported. The substance is used primarily in research settings for synthetic chemistry and proteomics applications, not as a pharmaceutical candidate requiring PK characterization.
|
| Toxicity/Toxicokinetics |
Acute toxicity data for Isoquinolin-1-amine (1532-84-9) are not widely reported in the available literature. The compound is classified as an intermediate and reagent requiring standard laboratory safety precautions. It may cause skin and eye irritation upon direct contact. Inhalation of dust or vapors should be avoided. The compound should be handled in a well-ventilated area with appropriate personal protective equipment (gloves, lab coat, safety goggles). Storage conditions include protection from light and inert atmosphere. Potential chronic toxicity has not been evaluated.
|
| References | |
| Additional Infomation |
Isoquinolin-1-amine (1532-84-9) has a molecular formula of C9H8N2 and molecular weight of 144.17 g/mol. Its IUPAC name is isoquinolin-1-amine. Additional synonyms include 1-aminoisoquinoline, isoquinolin-1-ylamine, and 1-isoquinolinamine. The compound appears as a light yellow to brown to dark green powder to crystal. Melting point range: 119-123degC. Purity: >98.0% by GC, >97.0% by neutralization titration. Storage: protected from light, under inert atmosphere (nitrogen or argon), at 4degC for short-term or -20degC for long-term storage. In solvent: -80degC for 6 months, -20degC for 1 month, protected from light.
|
| Molecular Formula |
C9H8N2
|
|---|---|
| Molecular Weight |
144.17
|
| Exact Mass |
144.069
|
| CAS # |
1532-84-9
|
| PubChem CID |
73742
|
| Appearance |
Light brown to brown solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C=CN=C2N
|
| InChi Key |
OSILBMSORKFRTB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8N2/c10-9-8-4-2-1-3-7(8)5-6-11-9/h1-6H,(H2,10,11)
|
| Chemical Name |
isoquinolin-1-amine
|
| Synonyms |
1-Aminoisoquinoline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.9363 mL | 34.6813 mL | 69.3626 mL | |
| 5 mM | 1.3873 mL | 6.9363 mL | 13.8725 mL | |
| 10 mM | 0.6936 mL | 3.4681 mL | 6.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
